Phencyclidine (PCP) induces
Phencyclidine (PCP) induces a psychotic state that closely resembles schizophrenia, most likely by blocking neurotransmission mediated at N -methyl-D -aspartate (NMDA)-type glutamate receptors (reviewed in Javitt and Zukin 1991) . Further, other NMDA antagonists (e.g., ketamine) also induce negative and cognitive symptoms similar to those of schizophrenia (Krystal et al. 1994 ) and rekindle presenting symptoms in remitted schizophrenic subjects (Lahti et al. 1995) , indicating that endogenous NMDA receptor dysfunction may contribute significantly to the pathophysiology of schizophrenia.
NMDA receptors contain binding sites for several modulatory compounds including glycine and polyamines. Binding of glycine to its modulatory site enhances NMDA receptor activation, indicating a potential role for glycine in the treatment of schizophrenia. In recent clinical studies, administration of 30-60 g/day (0.4-0.8 g/kg/day) of glycine was found to induce significant amelioration of negative and cognitive symptoms (reviewed in Heresco-Levy et al. 1996) . These doses are known to significantly elevate CNS glycine levels (D'Souza et al. 1995) . Similar results have been obtained with the partial glycine agonist D -cycloserine (Goff et al. 1995) . The potential usefulness of glycine for the treatment of schizophrenia has also been supported by studies demonstrating that glycine, but not other amino acids, significantly inhibited PCP-induced hyperactivity in rodents . In those studies, several glycine derivatives were found to effectively reverse PCP-induced hyperactivity, the most potent of which was glycyldodecylamide (GDA) ). Unlike glycine and other glycine derivatives, GDA treatment was found not to increase whole brain glycine levels, indicating that it was not functioning primarily as a glycine precursor. Recently, it has been demonstrated that GDA also does not bind to the NMDA-associated glycine binding site. However, GDA does antagonize synaptosomal glycine uptake by blocking glycine transport mediated by the "gly" transport system (Javitt and Frusciante 1996) . The "gly" system is a major regulator of extracellular glycine levels in brain. Moreover, an isoform of the GLYT1 transporter, which mediates gly system transport, is colocalized with NMDA receptors (Smith et al. 1992) . Thus, GLYT1 transporter-mediated uptake might function in part to maintain low synaptic glycine levels in the immediate vicinity of NMDA receptors. Inhibition of these transporters would raise glycine concentrations in the immediate vicinity of NMDA receptors by redistributing intra-and extracellular glycine without, necessarily, increasing whole brain glycine levels.
Although effects of glycine and GDA were first reported more than a decade ago, the finding that these agents inhibit PCP-induced hyperactivity following peripheral injection has not been confirmed. Moreover, the specificity of their effect has not been investigated. In particular, the possibility that they function by inducing nonspecific sedation or motor incoordination through interaction with hindbrain glycine receptors must be considered. The present study investigates effects of glycine and GDA on PCP-induced hyperactivity using a paradigm similar to that used previously . Moreover, potential non-specific effects of glycine are evaluated by investigating its effects on locomotor hyperactivity induced by amphetamine, a psychomotor stimulant that functions by modulating dopaminergic, rather than glutamatergic, neurotransmission.
GDA was synthesized in accordance with the methods of . Residual glycine was found to be Ͻ 0.1%. Rodent activity was monitored using a photocell-based activity meter (Columbus Instruments AutoTrack System, Columbus, OH). Animals were placed in test cages and allowed to accommodate overnight. On the day of experiment, animals, in their home cages, 3336 Ϯ 3356 (12) were placed on the activity monitors and baseline activity was monitored for 20 minutes, after which time animals were pretreated with either saline, glycine (0.8 g/kg intraperitoneally (i.p.)) or GDA (0.01-0.1 g/kg i.p.). Thirty minutes after pretreatment, animals were injected with either PCP (5 mg/kg i.p.) or amphetamine (5 mg/kg subcutaneously (s.c.)). Activity was then monitored for an additional 90 minutes. For statistical analyses, summed activity over the 60 minutes following PCP/amphetamine injection was used as a measure of drug-induced hyperactivity. Both PCP ( Figure 1A ) and amphetamine ( Figure 1B ) induced robust behavioral activation with the degree of activation produced by 5 mg/kg amphetamine being similar to that induced by 5 mg/kg PCP, albeit longer in duration. Despite the similarity in overall activation levels induced by the two agents, glycine-induced inhibition of activation differed between the two treatments. Glycine led to a significant reduction of PCPinduced hyperactivity to approximately 60% of control value (Table 1 ). In contrast, no significant effect of glycine was observed on amphetamine-induced hyperactivity. GDA induced a significant dose-dependent inhibition of PCP-induced hyperactivity. The degree of reduction induced by 0.05 g/kg GDA was similar to that induced by 0.8 g/kg glycine, indicating 16-fold greater potency. The degree of behavioral inhibition induced by 0.05 and 0.1 g/kg of GDA is similar to that reported previously ).
The present results confirm previous reports concerning the effectiveness of both glycine and GDA in inhibiting PCP-induced hyperactivity, and demonstrate that a dose of glycine that significantly inhibits PCPinduced hyperactivity does not inhibit hyperactivity induced by the dopaminergic agent amphetamine. To the extent that GDA functions as a glycine uptake inhibitor in vivo , these findings support the concept that glycine uptake inhibitors as a group may be more effective than glycine itself in reversing symptoms of PCP psychosis and schizophrenia. Glycine uptake antagonists with high potency and selectivity, however, must be developed before the potential usefulness of such agents in the treatment of PCP psychosis and schizophrenia can be definitively determined. The observation that glycine does not inhibit amphetamine-induced hyperactivity indicates that its antagonistic effects on PCP-induced hyperactivity cannot be accounted for by nonspecific effects such as sedation or incoordination. PCP induces its behavioral effects primarily by blocking NMDA receptors. PCP-induced NMDA blockade, in turn, leads to increased subcortical dopamine release which may mediate the hyperactivity induced by PCP and other NMDA antagonists. In contrast, amphetamine induces hyperactivity by directly stimulating dopamine release. The differential effect of glycine on PCP-versus amphetamine-induced hyperactivity may therefore be due to the fact that the locus of amphetamine effects are "downstream" from the NMDA receptor. Overall, the present findings support the need for continued development of NMDA potentiating agents for potential treatment of PCP-induced behavioral syndromes and schizophrenia.
